Rosen Law Firm says Aardvark investors may seek lead-plaintiff status in securities case
Rosen Law Firm says investors in Aardvark Therapeutics common stock may seek lead-plaintiff status in a securities class action, with an Oct. 13, 2026 deadline.
Rosen Law Firm says some Aardvark Therapeutics investors may qualify for a securities class action tied to the company’s 2025 IPO and later trading.
Rosen Law Firm said in an Aug. 27, 2026 notice that investors who purchased Aardvark Therapeutics, Inc. common stock pursuant and/or traceable to the company’s Feb. 13, 2025 initial public offering, as well as buyers of Aardvark securities between Feb. 13, 2025 and May 14, 2026, may be eligible to seek lead-plaintiff status in an already filed securities class action. The firm set an Oct. 13, 2026 deadline for investors who want to move forward in the case.
According to the notice, Rosen said investors may be entitled to compensation without out-of-pocket fees or costs through a contingency fee arrangement.
In the complaint described by the firm, plaintiffs allege defendants made materially false and/or misleading statements and failed to disclose adverse facts about Aardvark’s business, operations and prospects. The notice says the claims involve ARD-101, alleging that the drug was less safe than investors had been led to believe and that its clinical, regulatory and commercial prospects were overstated.
The notice also says investors suffered damages when the true details entered the market. It does not resolve the claims, and the allegations remain unproven unless and until a court rules otherwise.
Rosen Law Firm identified Aardvark by its Nasdaq ticker, AARD, and said it is providing contact information and a case-join URL for investors seeking to take part in the litigation or pursue lead-plaintiff status.
Investors covered by the stated class period would need to act by the Oct. 13, 2026 deadline if they want to seek appointment as lead plaintiff, according to the firm’s announcement.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()